New Polling Results on the use of cost-effectiveness assessments


In November, 2021, Morning Consult ran a poll, conducted biannually, on behalf of Partnership to Improve Patient Care, focusing on the use of cost-effectiveness assessments to determine the value of coverage and treatment costs. As in previous years, the survey found that Americans want patients and their doctors in charge of health care decision making and are opposed to the use of cost assessments such as Quality-Adjusted Life Year (QALY). Today, PIPC Chairman Tony Coelho published an opinion…

Boston Globe: How health care systems do, and do not, support patients


Effective treatment for people with some chronic diseases and disabilities is being denied as policy makers and insurers, trying to lower drug costs, keep looking to easy and simplistic formulas that are overtly discriminatory to determine what the treatments are worth, and who is worth treating.

Morning Consult: The Key to Addressing Rising Health Care Costs Is Patient-Centered Evidence


Few issues inspire more bipartisan concern than the rising cost of health care in the United States. To address this challenge, we must recognize that it is rooted in a simple fact: The overwhelming share of our health spending, 71 percent, goes toward care to help people living with multiple chronic conditions. Understanding this fact fundamentally shifts the paradigm in how to approach America’s health care challenges. We can create an affordable, high-quality health care system…

The Hill: Washington must help patients choose, not dictate their care


Over a decade ago, I founded the Partnership to Improve Patient Care with a basic principle: Patients are best served when they are informed and empowered to decide which care options are best for them; they are poorly served when policymakers in Washington dictate which options are best.

Real Clear Health: Congress Moves to Import Discriminatory Health Policies


Healthcare costs seem to be a constant discussion point both in Washington and in our state capitals. Policymakers are on a quest for a silver bullet that they can trumpet as a win to constituents, but this debate is complex, and nuanced; and will have enormous ramifications for American patients, like my daughter, Marissa, who lives with sickle cell disease and who has a new lease on life from innovative treatments.

Morning Consult: Drug Pricing Policy Must Prioritize Patients


The drug pricing debate continues to rage on, both at the federal level – look to H.R. 3, seen in the House in 2019 that imported foreign pricing models, which a recent Congressional Budget Office report acknowledges relied on the Quality-Adjusted Life Year to score savings – and in the states, like in my home state of Massachusetts, where our Health Policy Commission has signed a contract with the Institute for Clinical and Economic Review to develop a…

Washington State Wire: SB 5020 Includes Group Known for Discriminatory Practices


The cost of health care is high. Too high. There is discussion by federal and state lawmakers about policies to lower costs to protect patients and their families. I applaud the intent, but, as the parent of a child with cystic fibrosis (CF) and the leader of a patient advocacy organization, I believe they are missing the mark.

InsideSources: Socialized Medicine and Rationing COVID Care Defy American Principles


As an American, I’m proud to live in a country that is built on the inalienable rights of its citizens and the sacred principle that “all men are created equal.” However, as the parent of a child with spinal muscular atrophy (SMA) Type 1, I’ve realized that when it comes to our healthcare system — from rationing of care to the push to adopt drug policies from socialist nations — we don’t always live up…